| Non-Small Cell Lung Carcinoma
Mektovi vs Retevmo
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Mektovi vs Retevmo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRetevmo has a higher rate of injection site reactions vs Mektovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Retevmo but not Mektovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mektovi
Retevmo
At A Glance
Oral
Twice daily
MEK inhibitor
Oral
Twice daily
RET kinase inhibitor
Indications
- melanoma
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Medullary carcinoma of thyroid
- Thyroid carcinoma
Dosing
melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.
Non-Small Cell Lung Carcinoma, Medullary carcinoma of thyroid, Thyroid carcinoma Adults and adolescents >= 12 years: 120 mg orally twice daily (< 50 kg) or 160 mg orally twice daily (>= 50 kg); pediatric patients 2 to < 12 years: 40 mg three times daily to 160 mg twice daily orally based on body surface area; administered until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough
Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion
Most common (>=25%) edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, headache
Serious hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, slipped capital femoral epiphysis in adolescents
Postmarketing Stevens-Johnson Syndrome
Pharmacology
Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.
Selpercatinib is a kinase inhibitor that selectively inhibits wild-type RET and multiple mutated RET isoforms (including gene fusions and activating point mutations) as well as VEGFR1 and VEGFR3, and at clinically achievable concentrations also inhibits FGFR1, 2, and 3, blocking constitutive RET signaling that acts as an oncogenic driver promoting tumor cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mektovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
No coverage data available for Retevmo.
UnitedHealthcare
Mektovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Retevmo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Mektovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Retevmo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Mektovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Retevmo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MektoviView full Mektovi profile
RetevmoView full Retevmo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.